Kadimastem Ltd.

Kadimastem Ltd. Takes Another Step Towards Signing the #Merger Agreement with #nasdaq Listed IMCC #mergersandacquisitions

Kadimastem makes move towards #NASDAQ: Company Signs a MOU to Merge with a Company traded on the Nasdaq! #capitalmarkets #investment #merger

Kadimastem Ltd. Receives #patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for #diabetes in India   The patent approval in India strengthens the company’s global position in the diabetes field

A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology The publication presents the development and preclinical safety of Kadimastem's off the shelf AstroRx ("thaw to inject") cell product in comprehensive toxicity studies 

We are pleased to share that we have completed an INTERACT meeting with the FDA over the weekend and it was another milestone reached for the joint collaboration with iTolerance, Inc. as we now can move forward with pre-clinical and clinical plans for the joint project together after some guidance and assurance from the FDA.

Kadimastem Ltd. and iTolerance, Inc. are in the middle of an exiting collaboration project to co-develop cell technology as a potential cure for diabetes without the need for chronic immunosuppression! We have begun communication with the FDA for this much needed cure and are working towards the next steps! Wishing you all a joyous holiday season and happy new year!

We at Kadimastem Ltd. are wishing all who celebrate a very Marry Christmas and to all a very prosperous new years, we wish for peace to all and happiness.

Kadimastem and iTolerance, Inc. Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with #FDA for Potential #cure for #type1diabetes

Kadimastem is happy to report that it has been granted a #patent from the United States Patent and Trademark Office for its #celltherapy #technology. This patent covers the production of IsletRx, the company's product for the treatment and potential #cure for #diabetes.   Link to the full article:

Prof. Ariel Revel at Biotechnology Innovation Organization in #boston talking about our AstroRx cell technology and our vision to treat #ALS patients on their podcast at the conference! #technology #biotechnology #innovation #podcast